Modalis Therapeutics Corporation (4883) Other
Market cap
¥4.8B
P/E ratio
Modernalis develops gene therapies for rare diseases using safe CRISPR-GNDM technology that controls genes without cutting DNA strands.
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Return on Assets | - | - | -4.6 | -9 | -30.3 | -31.4 | -9 | -10.5 |
| Return on equity (%) | - | |||||||
| Employees | 10 | 16 | 20 | 26 | 36 | 37 | 14 | 17 |